Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Illuminare-1 for nerve imaging in prostate cancer surgery
NCT04983862Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rizedisben in prostate adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Safety of Illuminare-1 up to 45 days. Started Oct 2021; status: completed.
02
Drugs
rizedisben
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04983862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983862.